Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals (GLMD) Stock Price & Analysis


GLMD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.43 - $14.18
Previous Close$4.34
Average Volume (3M)24.43K
Market Cap
Enterprise Value-$6.04M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$578.00K
Price to Earnings (P/E)-0.5
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.08
Shares Outstanding21,113,066
10 Day Avg. Volume7,066
30 Day Avg. Volume24,433
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.79
Enterprise Value/Ebitda0.40
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $3.43 and its highest was $14.18 in the past 12 months.
    What is Galmed Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Galmed Pharmaceuticals’s upcoming earnings report date?
    Galmed Pharmaceuticals’s upcoming earnings report date is Aug 03, 2023 which is in 55 days.
      How were Galmed Pharmaceuticals’s earnings last quarter?
      Galmed Pharmaceuticals released its earnings results on Jun 01, 2023. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.5 by $0.41.
        Is Galmed Pharmaceuticals overvalued?
        According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Galmed Pharmaceuticals pay dividends?
          Galmed Pharmaceuticals does not currently pay dividends.
          What is Galmed Pharmaceuticals’s EPS estimate?
          Galmed Pharmaceuticals’s EPS estimate is -$1.5.
            How many shares outstanding does Galmed Pharmaceuticals have?
            Galmed Pharmaceuticals has 1,680,226 shares outstanding.
              What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
              Galmed Pharmaceuticals reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.5. Following the earnings report the stock price went up 0.434%.
                Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
                Among the largest hedge funds holding Galmed Pharmaceuticals’s share is PYA Waltman Capital, LLC. It holds Galmed Pharmaceuticals’s shares valued at N/A.


                  Galmed Pharmaceuticals Stock Smart Score

                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Galmed Pharmaceuticals

                  Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Agile Therapeutics
                  Kala Pharmaceuticals
                  Karyopharm Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis